Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment

Journal of Hepatology

Volumn 65, Issue 4, 2016, Pages 862-864

  Torres, Harrys A ^a   Vauthey, Jean Nicolas ^a   Economides, Minas Platon ^a   Mahale, Parag ^a   Kaseb, Ahmed ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ABDOMINAL RADIOGRAPHY; ANTIVIRAL THERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; DISEASE ASSOCIATION; FOLLOW UP; HEPATITIS C; HUMAN; LETTER; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; TIME TO TREATMENT; LIVER TUMOR; TREATMENT WITHDRAWAL; TUMOR RECURRENCE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; WITHHOLDING TREATMENT;

EID: 84991712988     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.034     Document Type: Letter

References (6)

1. [1] Reig, M., Marino, Z., Perello, C., et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
2. [2] Kyvernitakis, A., Mahale, P., Popat, U.R., et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant 22 (2016), 717–722.
3. [3] Torres, H.A., Mahale, P., Blechacz, B., et al. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Canc Netw 13 (2015), 41–50.
4. [4] European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
5. [5] National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: hepatobiliary cancers, 2015; Version 2.
6. [6] Bruix, J., Sherman, M., American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.